Citable filing context
STE's research view summarizes recent SEC filing context, starting with management_change from Aug 6, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 6, 2026 | management_change | STERIS plc appointed Pierre Boulud to the Audit Committee and the Compliance and Technology Committee. |
| Aug 6, 2026 | other | STERIS plc held its 2026 Annual General Meeting of Shareholders on July 31, 2026. |
| Aug 5, 2026 | restructuring | STERIS announced a consolidation plan with $55M-$70M in restructuring charges to open a North Carolina facility. |
| Aug 5, 2026 | Guidance: adjusted_eps | 11.10 to 11.30 |
| Aug 5, 2026 | Guidance: capital_expenditures | not reported to 450.00 |
| Aug 5, 2026 | Guidance: constant_currency_organic_revenue_growth | 6.00 to 7.00 |
| Aug 7, 2026 | mda_quarterly | STERIS reported strong financial performance for the first quarter of fiscal 2027, with total revenues rising 7.3% to $1.49 billion. Growth was driven by increased volume in the Healthcare and Life Sciences segments, alongside pricing gains across all three business units: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Gross profit margin improved to 45.8% from 45.1% in the prior-year period, as pricing, productivity, and favorable product mix offset inflationary pressures. Income from operations rose to $285.8 million, up from $246.0 million. The company continues to execute its growth strategy through tuck-in acquisitions, completing three such transactions in the Healthcare segment during the quarter for $17.3 million. While cash flow from operations decreased to $367.1 million due to working capital fluctuations, the company maintains a solid liquidity position with a 20.9% debt-to-total capital ratio. Looking ahead, STERIS announced a new restructuring plan on August 5, 2026, to consolidate formulated chemistries manufacturing into a North Carolina Center of Excellence. This initiative, expected to conclude by fiscal 2030, involves closing facilities in Missouri and Minnesota and is projected to incur $55 million to $70 million in pre-tax charges. Management remains focused on innovation in infection prevention and procedural technologies. |
| May 29, 2026 | mda | STERIS reported fiscal 2026 revenues of $5,935.9 million, an 8.7% increase driven by organic volume growth, pricing, and favorable foreign currency movements. Operating income rose 27.1% to $1,101.8 million, benefiting from higher pricing and a reduction in restructuring and litigation costs. The company’s three reportable segments—Healthcare, AST, and Life Sciences—all experienced growth, with Life Sciences capital equipment revenues notably increasing 15.5%. Gross profit margin expanded to 44.2%, as pricing and productivity gains offset headwinds from inflation and tariffs. Following the fiscal 2025 divestiture of the Dental segment for $787.5 million, which was primarily used to pay down debt, the debt-to-total capital ratio improved to 21.3%. Free cash flow grew to $982.9 million. Key strategic events included the settlement of Illinois EO litigation for $48.2 million and the completion of a restructuring plan targeting the European surgical business. Capital allocation remains aggressive, highlighted by a new $1 billion share repurchase program authorized in May 2026 and increased quarterly dividends. Long-term growth is underpinned by an aging global population and rising demand for preventive screenings, such as endoscopies and colonoscopies. |
Source: SEC EDGAR filing text and events; period Aug 6, 2026; filed Aug 6, 2026.
STE company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.